CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company, announced the successful closing of a $14 million private placement financing on March 16, 2026. This financing was executed through a Securities Purchase Agreement with selected accredited investors, allowing the company to issue 2,867,089 shares of its common stock at a price of $4.883 per share, reflecting a 5% discount to the closing price on March 16. The company plans to utilize the net proceeds from this financing for various corporate purposes, including sales and marketing, research and development, and general administrative expenses. The shares sold in this private placement have not been registered under the Securities Act of 1933 and were offered under an exemption from registration. CapsoVision also provided preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, reporting fourth-quarter revenue of $3.9 million and full-year revenue of $13.6 million. The company had approximately $10.1 million in cash and equivalents as of December 31, 2025. The company is scheduled to release its detailed financial results on March 26, 2026, and will host a conference call to discuss these results and provide a corporate update.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.